In the latest trading session, BioDelivery Sciences International closed at $4.73, marking a -0.63% move from the previous day. This change lagged the S&P 500's 0.35% loss on the day. Meanwhile, the Dow lost 0.4%, and the Nasdaq, a tech-heavy index, lost 0.39%.
Prior to today's trading, shares of the specialty pharmaceutical company had gained 16.67% over the past month. This has outpaced the Medical sector's gain of 3.02% and the S&P 500's gain of 4.48% in that time.
Wall Street will be looking for positivity from BDSI as it approaches its next earnings report date. The company is expected to report EPS of -$0.10, up 65.52% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $16.15 million, up 29.1% from the year-ago period.
Investors should also note any recent changes to analyst estimates for BDSI. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection has moved 8.33% higher. BDSI is currently sporting a Zacks Rank of #1 (Strong Buy).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 75, putting it in the top 30% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
Image: Bigstock
BioDelivery Sciences International (BDSI) Dips More Than Broader Markets: What You Should Know
In the latest trading session, BioDelivery Sciences International closed at $4.73, marking a -0.63% move from the previous day. This change lagged the S&P 500's 0.35% loss on the day. Meanwhile, the Dow lost 0.4%, and the Nasdaq, a tech-heavy index, lost 0.39%.
Prior to today's trading, shares of the specialty pharmaceutical company had gained 16.67% over the past month. This has outpaced the Medical sector's gain of 3.02% and the S&P 500's gain of 4.48% in that time.
Wall Street will be looking for positivity from BDSI as it approaches its next earnings report date. The company is expected to report EPS of -$0.10, up 65.52% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $16.15 million, up 29.1% from the year-ago period.
Investors should also note any recent changes to analyst estimates for BDSI. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection has moved 8.33% higher. BDSI is currently sporting a Zacks Rank of #1 (Strong Buy).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 75, putting it in the top 30% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.